Literature DB >> 8924056

Effects of felodipine on the ischemic heart: insight into the mechanism of cytoprotection.

R Ferrari1, A Cargnoni, P Bernocchi, G Gaia, M Benigno, E Pasini, P Pedersini, C Ceconi.   

Abstract

To assess whether the administration of felodipine protects the myocardium in a dose-dependent manner against ischemia and reperfusion, isolated rabbit hearts were infused with three different concentrations of felodipine: 10(-10), 10(-9), and 10(-8) M. Diastolic and developed pressures were monitored; coronary effluent was collected and assayed for CPK activity and for noradrenaline concentration; mitochondria were harvested and assayed for respiratory activity; and ATP production and calcium content and tissue concentration of ATP, creatine phosphate (CP), and calcium were determined. The occurrence of oxidative stress during ischemia and reperfusion was also monitored in terms of tissue content and release of reduced (GSH) and oxidized (GSSG) glutathione. Treatment with felodipine at 10(-10) and 10(-9) M had no effect on the hearts when perfused under aerobic conditions, whilst the higher dose reduced developed pressure from 57.7 +/- 2.6 to 30.0 +/- 2.6 mmHg (p < 0.01). On reperfusion treated hearts recovered better than the untreated hearts with respect to left ventricular performance, replenishment of ATP and CP stores, and mitochondrial function. Recovery of developed pressure was 100% at 10(-8) M, 55% at 10(-9) M, and 46% at 10(-10) M. The reperfusion-induced tissue and mitochondrial calcium overload, release of CPK and noradrenaline, and oxidative stress were also significantly reduced. The effects of felodipine were dose dependent. Felodipine inhibited the initial rate of ATP-driven calcium uptake but failed to affect the initial rate of mitochondrial calcium transport. It is concluded that felodipine infusion provides dose-dependent protection of the heart against ischemia and reperfusion. Because this protection also occurred at 10(-9) M and 10(-10) M in the absence of a negative inotropic effect during normoxia and of a coronary dilatory effect during ischaemia, it cannot be attributed to an energy-sparing effect or to improvement in oxygen delivery. From our data we can envisage two other major mechanisms-(1) membrane protection and (2) reduction in oxygen toxicity. The ATP-sparing effect occurring at 10(-8) M is likely to be responsible for the further protection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8924056     DOI: 10.1007/bf00051107

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  51 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

Review 2.  Reperfusion injury and its pharmacologic modification.

Authors:  L H Opie
Journal:  Circulation       Date:  1989-10       Impact factor: 29.690

3.  Abnormal mitochondrial oxidative phosphorylation of ischemic myocardium reversed by Ca2+-chelating agents.

Authors:  C F Peng; J J Kane; M L Murphy; K D Straub
Journal:  J Mol Cell Cardiol       Date:  1977-11       Impact factor: 5.000

4.  Mitochondria and sarcoplasmic reticulum function in cardiac hypertrophy and failure.

Authors:  L A Sordahl; W B McCollum; W G Wood; A Schwartz
Journal:  Am J Physiol       Date:  1973-03

Review 5.  Calcium channel antagonists, Part I: Fundamental properties: mechanisms, classification, sites of action.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1987-12       Impact factor: 3.727

6.  Prevention of reperfusion damage in working rat hearts by calcium antagonists and calmodulin antagonists.

Authors:  A J Higgins; K J Blackburn
Journal:  J Mol Cell Cardiol       Date:  1984-05       Impact factor: 5.000

7.  Effects of nicardipine, a calcium antagonist, on myocardial salvage and high energy phosphate stores in reperfused myocardial injury.

Authors:  W W Holt; M F Wendland; N Derugin; C Wolfe; M Saeed; C B Higgins
Journal:  J Am Coll Cardiol       Date:  1990-12       Impact factor: 24.094

8.  Felodipine in chronic stable angina: a randomized, double-blind, placebo-controlled, crossover study.

Authors:  P Sangiorgio; G Di Pasquale; S Savonitto; S Urbinati; A Rubboli; G Cavallotti; G Pinelli; D Bracchetti
Journal:  Eur Heart J       Date:  1990-11       Impact factor: 29.983

9.  Inhibitory effect of calcium antagonists on the depletion of cardiac norepinephrine during postischemic reperfusion.

Authors:  W G Nayler; W J Sturrock
Journal:  J Cardiovasc Pharmacol       Date:  1985 May-Jun       Impact factor: 3.105

10.  Acute and chronic efficacy of felodipine in congestive heart failure.

Authors:  P Agostoni; E Doria; S Riva; A Polese
Journal:  Int J Cardiol       Date:  1991-01       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.